Drug intelligence / Profile preview

PGN-1001

Development stage: Preclinical
Lead developer: Shenzhen Puruijin Biological Pharmaceutical
Modality: Gene Therapies

Overview

PGN-1001 is a preclinical gene therapy developed by Pregene in collaboration with Gilead Sciences. This innovative therapeutic approach is designed to enable a patient's own cells to produce a broadly neutralizing antibody, which targets the Human Immunodeficiency Virus (HIV). The primary goal of PGN-1001 is to contribute to HIV cure research by providing a sustained, endogenous production of anti-HIV antibodies.

Beyond the preview

Go deeper on PGN-1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PGN-1001.

Explore the full profile